"We are at your service"
5890 Imperial Loop, Suite 12
College Station, TX 77845
Phone: (925) 353-7872
MDx BioAnalytical Laboratory, Inc. was established in Oro Valley, AZ approximately 20 miles north of Tucson in 2008 and moved to College Station, TX in August of 2010. The Company’s strength lies in the background, skills and experiences of it management and technical team. Earl White, Ph.D., President and CEO directs MDx BioAnalytical laboratory research program. Dr. White was Vice President, Analytical and Pharmaceutical Sciences for Integrated Biomolecule Corporation from July 2007 to November, 2008. Previously, he served as Vice President of Advance Analytical Sciences for Large Scale Biology Corp (LSBC) and Predictive Diagnostics, Inc. (PDI) whose parent company was LSBC, a publicly-traded company. Dr. White joined LSBC in 1998 as a Senior Scientist and established the Analytical Center of Excellence. A year later he was promoted to Director of Advanced Analytical Resources and served as Director of Quality Control for LSBC's Non-Hodgkin’s Lymphoma (NHL) cancer vaccines program, the Company's first clinical product candidate. In 2002, he was appointed Vice President, Advanced Analytical Sciences. Prior to joining LSBC, Dr. White was Sr. Staff Scientist and Head of the Mass Spectrometry Group in the Research and Development Department of R.J. Reynolds Tobacco Company from 1985-1998. Dr. White started his career as a forensic toxicologist with the Mississippi State Crime Laboratory. Dr. White received the B.S. and M.S degrees in chemistry from Jackson State University in Jackson, MS and a Ph.D. degree in analytical chemistry from the University of North Carolina at Chapel Hill, NC where he specialized in mass spectrometry.
The company has two primary focuses. The first is providing analytical research and services to pharmaceutical companies, including start-ups and virtual companies. This is a niche market that MDx will focus on since many of these companies do not have their own analytical facilities. Secondly, MDx BioAnalytical plans to become the number one molecular diagnostics company employing algorithms for identifying biomarkers in many diseases including autoimmune diseases such as Sjögren’s Syndrome (SjS), Alzheimer’s disease and many oncology diseases.